drugset

drugset / Trial / NCT02580474

The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

NCT02580474 ↗

Phase 4 Completed 21 enrolled Myeong Jun Song Bristol-Myers Squibb · collab Cheongju St. Mary's Hospital, Cheongju, Korea · collab Chungnam National University Hospital · collab Dankook University · collab Eulji General Hospital · collab Eulji University Hospital · collab Konkuk University Hospital · collab Konyang University Hospital · collab Korea University Guro Hospital · collab Saint Vincent's Hospital, Korea · collab Severance Hospital · collab Soonchunhyang University Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

Safety and Efficacy of DAAs (Daclatasvir+Asunaprevir) in patients with chronic hepatitis C and chronic renal failure will be assessed.

Timeline

Start: 2016-02
Primary completion: 2018-04
Completion: 2018-04

Publications

Lee BS, Song MJ, Kwon JH, Lee TH, Jang JW, Kim SH, Lee SH, Kim HS, Kim JH, Kim SB, Ko SY, Song DS. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis. Gut Liver. 2019 Mar 15;13(2):191-196. doi: 10.5009/gnl18240.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Asunaprevir	Small molecule	—	—
Subject	Daclatasvir	Small molecule	—	—

Indications